Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic, Inc. announced the start of the patient cohorts in its ongoing Phase I clinical trial of IMU-856, the company’s third clinical asset, in patients with celiac disease.